Table 2 Univariate and multivariable analyses for overall survival
Characteristic | Univariate analysis | Multivariablea analysis | ||||
|---|---|---|---|---|---|---|
No. evt/ No. pts | Median OS (95% CI) | HR [95% CI] | P-value | HR [95% CI] | P-value | |
Age (years) | 1.04 [1.00; 1.08] | 0.034 | ||||
Sex | ||||||
Male | 17/37 | 22 (20; NR) | 1 | 0.900 | ||
Female | 15/38 | 21 (20; NR | 1.05 [0.52; 2.1] | |||
ECOG Performance status | ||||||
0–1 | 32/68 | 21 (20; 24) | NA | NA | ||
2 | 0/7 | NA | NA | |||
Number of metastatic sites | ||||||
1 | 11/28 | 22 (20; NA) | 1 | 0.500 | ||
≥ 2 | 21/47 | 22 (19; NA) | 1.29 [0.62; 2.68] | |||
Treatment | ||||||
XELIRI | 11/31 | 22 (20; NA) | 1 | 0.150 | ||
FOLFIRI | 21/44 | 21 (20; 24) | 1.71 [0.82; 3.56] | |||
Body mass index category (kg/m2) | ||||||
< 25 | 22/45 | 21 (19; NA) | 1 | 0.180 | ||
≥ 25 | 10/30 | 24 (21; NA) | 0.60 [0.28; 1.26] | |||
Model 1: SMM depletion at baseline | ||||||
No | 13/35 | 24 (20; NA) | 1 | 0.150 | 1 | 0.791 |
Yes | 19/40 | 21 (20; 23) | 1.69 [0.83; 3.43] | 1.14 [0.44; 2.98] | ||
Model 2: L3 skeletal muscle score | 0.65 [0.45; 0.94] | 0.023 | 0.71 [0.41; 1.22] | 0.211 | ||
Model 3: L3 visceral adipose tissue score | 1.03 [0.71; 1.48] | 0.880 | 1.05 [0.67; 1.64] | 0.833 | ||
Model 4: L3 subcutaneous adipose tissue score | 0.68 [0.46; 1.01] | 0.054 | 0.71 [0.44; 1.14] | 0.153 | ||
Model 5: L3 total adipose tissue score | 0.84 [0.57; 1.23] | 0.370 | 0.87 [0.53; 1.38] | 0.557 | ||
Model 6: Skeletal muscle density (HU) | 0.98 [0.94; 1.01] | 0.210 | 1.01 [0.95; 1.06] | 0.868 | ||